345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010)

• Lu Xu,
• Se Hoon Park,
• Evan Yu,
• Yi-Hsiu Huang,
• Jeri Kim

Affiliations

Lu Xu

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China

Se Hoon Park

Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Evan Yu

1University of Washington, Seattle, WA, USA

Yi-Hsiu Huang

3Taipei Veterans General Hospital, Taipei, Taiwan, Province of China

Jeri Kim

5Merck and Co, Inc., Kenilworth, NJ, USA